Saccharomyces boulardii CNCM I-745: A chance discovery of a unique probiotic drug in the jungles of South East Asia
- 3 min
The Saccharomyces boulardii CNCM I-745 story began in the jungles of South East Asia…
In 19231, while on an expedition in South East Asia, the French microbiologist Henri Boulard made a chance discovery. He observed locals drinking a concoction made from the skins of two tropical fruits, litchis and mangosteens, to relieve stomach problems, including diarrhea.2,3
The special ingredient in this anti-diarrheal remedy was found to be a single yeast strain and Henri Boulard called it Saccharomyces boulardii.2
(Internal code : 20.60)
This yeast is unique in the fact that it is from the Saccharomyces cerevisiae family but displays properties that separate it from S. Cerevisiae.3 It is some of these unique properties make it well suited to be a probiotic, including a tolerance of acid and the fact that it grows at 37°C (human body temperature).3
S. boulardii CNCM I-745 is the first yeast to be demonstrated to have probiotic properties and the first probiotic in human medicine.2 The yeast has been investigated in more than 100clinical trials and has been available as a probiotic treatment for diarrhea for over 56 years!
(Internal code : 20.60)
Since it was discovered and then used as a probiotic drug , S. boulardii CNCM I-745 has been used to treat, prevent and recover from diarrhea.2 S. boulardii CNCM I-745 also creates a favourable growth environment for the beneficial gut microbiota after an imbalance created by diarrhea.1,*
Saccharomyces boulardii CNCM I-745 is a probiotic with a unique and long history whose story continues to this very day!
*The prescribed usage of Saccharomyces boulardii CNCM I-745 for different conditions varies country to country. Please refer to your local Product Information, or speak with your doctor or pharmacist.
Internal code : 20.25
- 01 . More MI, and Swidsinski, A. Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis–a review. Clinical and experimental gastroenterology. 2015; 8: 237.
- 02 . Joly, F et al. 2017. Saccharomyces boulardii CNCM I-745. Marteau, P and Dore J (Ed.), Gut Microbiota: A full-fledged organ. 2017: 305-326. Paris: John Libbey Eurotext.
- 03 . Czerucka, D., T. Piche, and P. Rampal. Yeast as probiotics–Saccharomyces boulardii. Alimentary pharmacology & therapeutics. 2007; 26(6): 767-778.